A one-time injection of Lumevoq demonstrated sustained visual acuity improvements with a favorable safety profile at 5 years in patients with Leber hereditary optic neuropathy, according to a press release from GenSight Biologics.
“The REFLECT trial confirms the durability of the treatment benefit from a one-time intravitreal injection of Lumevoq, which will address a frequent question raised by regulatory authorities regarding gene therapies: Will the treatment effect fade over time?” Magali Taiel, MD, chief medical officer of GenSight Biologics, told Healio.
The phase 3